(Q37942292)

25 August 2017

1 reference

title

Optimization of conventional therapy in patients with IBD. (English)

1 reference

25 August 2017

Kirstin M Taylor

1

1 reference

25 August 2017

Peter M Irving

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

4 October 2011

1 reference

Nature Reviews Gastroenterology & Hepatology

25 August 2017

published in

1 reference

25 August 2017

volume

8

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

646-656

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2011.172

25 August 2017

exact match

0 references

cites work

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Review article: appropriate use of corticosteroids in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Systematic review: adherence issues in the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

AGA technical review on perianal Crohn’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Preliminary study of ciprofloxacin in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Therapy of Metronidazole With Azathioprine to Prevent Postoperative Recurrence of Crohn's Disease: A Controlled Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Topical metronidazole treatment in pouchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Effect of early immunomodulator use in moderate to severe pediatric Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

The efficacy of methotrexate for maintaining remission in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Efficacy of parenteral methotrexate in refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Optimizing conventional therapies for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Nonadherence in inflammatory bowel disease: results of factor analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Distribution of mesalazine enemas in active and quiescent ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Budesonide for induction of remission in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Methotrexate for induction of remission in refractory Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Methotrexate for maintenance of remission in Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Oral methotrexate in ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Methotrexate bioavailability after oral and intramuscular administration in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.172

A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration

31 March 2020

1 reference

12 December 2020

Metronidazole in Crohn's disease. A double blind cross-over clinical trial

1 reference

12 December 2020

Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study

1 reference

12 December 2020

Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity

1 reference

12 December 2020

Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.

1 reference

12 December 2020

A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis

1 reference

12 December 2020

Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis

1 reference

12 December 2020

Metronidazole therapy for perineal Crohn's disease: a follow-up study

1 reference

12 December 2020

10.1038/NRGASTRO.2011.172

Identifiers

DOI

1 reference

25 August 2017

1 reference